Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...
The companies will also evaluate zanzalintinib with WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for ...
Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), ...
Belzutifan (Welireg) is available during the managed access period. It is a possible treatment for tumours associated with von Hippel-Lindau (VHL) disease in adults when localised procedures such as ...
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...
Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...